Clinical outcome and prognostic factors for ischaemic ulcers treated with PTA in lower limbs

European Journal of Vascular and Endovascular Surgery

Volumn 24, Issue 2, 2002, Pages 176-181

  Mlekusch, W ^a   Schillinger, M ^a   Sabeti, S ^a   Maca, T ^a   Ahmadi, R ^a   Minar, E ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Diabetes mellitus; Lipoprotein(a); Peripheral arterial disease

Indexed keywords

AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; ISCHEMIA; LEG; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROGNOSIS; RESTENOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; ULCER HEALING; FEMORAL ARTERY; FOLLOW UP; HOSPITALIZATION; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPLITEAL ARTERY; TIME; ULCER; VASCULARIZATION;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON; ARTERIAL OCCLUSIVE DISEASES; FEMALE; FEMORAL ARTERY; FOLLOW-UP STUDIES; HUMANS; ISCHEMIA; LEG; MALE; OUTCOME ASSESSMENT (HEALTH CARE); POPLITEAL ARTERY; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; ULCER;

EID: 0036690606     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1053/ejvs.2002.1700     Document Type: Article

References (42)

1. TRANS ATLANTIC INTER-SOCIETY CONSENSUS (TASC). Management of peripheral arterial disease (PAD). Eur J Vasc Endovasc Surg 2000; 19: S1-250.
2. LENG GC, FOWKES FGR. The Edinburgh Claudication Questionnaire: an improved version of the WHO/Rose Questionnaire for use in epidemiological surveys. J Clin Epidemiol 1992; 45: 1101-1109.
3. BARNHORST DA, BARNER HB. Prevalence of congenitally absent pedal pulses. N Engl J Med 1968; 278: 264-265.
4. DRUMMOND M, DAVIS L. Economic evaluation of drugs in peripheral vascular disease and stroke. J Cardiovasc Pharmakology 1994; 23: S4-S7.
5. KINNISON ML, WHITE RI, BOWERS WP, DUNLAP ED. Cost incentives for peripheral angioplasty. AJR Am J Roentgenol 1985; 145: 1241-1244.
6. BALLARD JL, BERGAN JJ, SINGH P, YONEMOTO H, KILLEEN JD. Aortoiliac stent deployment versus surgical reconstruction: Analysis of outcome and cost. J Vasc Surg 1998; 28: 94-101.
7. SINGH S, EVANS L, DATTA D, GAINES P, BEARD JD. The costs of managing lower limb-threatening ischemia. Eur J Endovasc Surg 1996; 12: 359-362.
8. MACKEY WC, MCCULLOUGH JL, CONLON TB et al. The cost of surgery for limb-threatening ischemia. Surgery 1986; 99: 26-35.
9. JOHNSON BF, EVANS L, DRURY R et al. Surgery for limb threatening ischemia: a reappraisal of the costs and benefits. Eur J Vasc Endovasc Surg 1995; 9: 181-188.
10. REIFSNYDER T, GROSSMAN JP, LEERS SA. Limb loss after lower extremity bypass. Am J Surg 1997; 174: 149-151.
11. WOLFE JH, WYATT MG. Critical and subcritical ischemia. Eur J Vasc Endovasc Surg 1997; 13: 578-582.
12. SCHNEIDER E, GRUNTZIG A, BOLLINGER A. Percutaneous transluminal angioplasty (PTA) in stages III and IV of peripheral arterial occlusive disease. VASA 1982; 11: 336-339.
13. KANNEL WB, MCGEE DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979; 241: 2035-2038.
14. STOUT RW. Diabetes, atherosclerosis and aging. Diabetes Care 1990; 13: 20-23.
15. DORMANDY JA, GOYLE KB, REID HL. Treatment of severe intermittent claudication by controlled defibrination Lancet 1977; 1: 625.
16. LASSEN NA, LARSEN O, SORENSON AW et al. Conservative treatment of gangrene using mineralcorticoid-induced hypertension. Lancet 1968; 1: 606-609.
17. SZCZEKLIK A, NIZANKOWSKI R, SLAWINSKI S et al. Successful therapy of advanced arteriosclerosis obliterans with prostacyclin. Lancet 1979; 1: 1111-1114.
18. DIEHM C, HÜBSCH-MÜLLER C, STAMMLER F. Intravenöse Prostaglandin E1-Therapie bei Patienten mit peripherer arterieller Verschlusskrankheit (AVK) im Stadium III: Eine doppelblinde, Placebokontrollierte Studie. In: Heinrich H, Böhme H, Rogatti W, eds. Prostaglandin E1-Wirkungen und therapeutische Wirksamkeit. Heidelberg: Springer-Verlag 1988; 133-143.
19. WIEMAN TJ. Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group. Am J Surg 1998; 176: 74S-79S.
20. UK SEVERE LIMB ISCHEMIA STUDY GROUP. Treatment of limb threatening ischemia with intravenous Iloprost: A randomised double-blind placebo controlled study. Eur J Vasc Surg 1991; 5: 511-516.
21. HESS H, MITASCHK A, DEICHSEL G. Drug induced inhibition of platelet function delays progression in peripheral occlusive arterial disease: a prospective double-blind arteriographically controlled trial. Lancet 1985; 1: 415-419.
22. TAYLOR LM, EDWARDS JM, PORTER JM. Present status of reversed vein bypass grafting: five-year result of modern series. J Vasc Surg 1990; 11: 193-206.
23. BELKIN M, KNOX J, DONALDSON MC, MANNICK JA, WHITTEMORE AD. Infrainguinal arterial reconstruction with non-reversed greater saphenous vein. J Vasc Surg 1996; 24: 957-962.
24. BAKAL CW, CYNAMON J, SPRAYREGEN S. Infrapopliteal percutaneous transluminal angioplasty: what we know. Radiology 1996; 200: 36-43.
25. HORVATH W, OERTL M, HAIDINGER D. Percutaneous transluminal angioplasty for crural arteries. Radiology 1990; 177: 565-569.
26. SCHWARTEN DE, CUTCLIFF WB. Arterial occlusive disease below the knee: treatment with percutaneous transluminal angioplasty performed with low-profile catheters and steerable guide-wires. Radiology 1988; 169: 71-74.
27. BERCELLI SA, CHAN AK, POMPOSELLI FB et al. Efficacy of dorsal pedal artery bypass in limb salvage for ischemic heel ulcers. J Vasc Surg 1999; 30: 499-508.
28. MINAR E, POKRAJAC B, AHMADI R et al. Brachytherapy for prophylaxis of restenosis after long-segment femoropopliteal angioplasty: pilot study. Radiology 1998; 208: 173-179.
29. EXNER M, SCHILLINGER M, MINAR E et al. Heme oxygenase-1 microsatellite gene promoter polymorphism is associated with restenosis after percutaneous transluminal angioplasty. J Endovasc Ther 2001; 8: 433-440.
30. SCHILLINGER M, HAUMER M, SCHLERKA G et al. Restenosis after percutaneous transluminal angioplasty in patients with peripheral artery disease: the role of inflammation. J Endovasc Ther 2001; 8: 477-483.
31. TREIMAN GS, ODERICH GS, ASHRAFI A, SCHNEIDER PA. Management of ischemic heel ulceration and gangrene: An evaluation of factors associated with successful heeling. J Vasc Surg 2000; 31: 1110-1118.
32. CREW JR, THUENER M. Wound healing: An endpoint for complex peripheral angioplasty. J Endovasc Surg 1994; 1: 88-91.
33. ZIMNY S, DESSEL F, EHREN M, PFOHL M, SCHATZ H. Early Detection of microcirculatory impairment in diabetic patients with foot at risk. Diabetes Care 2001; 24: 1810-1814.
34. SUMPIO BE. Foot ulcers. N Engl J Med 2000; 343: 787-793.
35. SAUSENG S, KASTENBAUER T, SOKOL G, IRSIGLER K. Estimation of risk for plantar ulceration in diabetic patients with neuropathy. Diabetes Nutr Metab 1999; 12: 189-193.
36. BILD DE, SELBY JV, SINNOCK P et al. Lower extremity amputation in people with diabetes mellitus: epidemiology and prevention. Diabetes Care 1989; 12: 24-31.
37. UBBINK DT, TULEVSKI II, LEGEMATE DA, JACOBS MJ. Diabetes mellitus is not a contra-indication for peripheral vascular intervention in patients with leg ischemia. VASA 1997; 26: 39.
38. HILL SL, HOLTZMAN GI, BUSE R. The effects of peripheral vascular disease with osteomyelitis in the diabetic foot. Am J Surg 1999; 177: 282-286.
39. MACA T, AHMADI R, DERFLER K et al. Elevated lipoprotein(a) and increased incidence of restenosis after femoropopliteal PTA. Rationale for the higher risk of recurrence in females? Atherosclerosis 1996; 127: 27-34.
40. STROES E, DE BRUIN T, DE VALK H et al. NO activity in familial combined hyperlipidemia: potential role of cholesterol remnants. Cardiovasc Res 1997; 36: 445-452.
41. RUBANYI GM, FREAY AD, LAWN RM. Endothelium-dependent vasorelaxation in the aorta of transgenic mice expressing human apolipoprotein(a) or lipoprotein(a). Endothelium 2000; 7: 253-264.
42. SCHLAICH MP, JOHN S, LANGENFELD MR et al. Does lipoprotein(a) impair endothelial function? J Am Coll Cardiol 1998; 31: 359-365.